No Data
No Data
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Apogee Therapeutics Welcomes Dr. Bollinger to Board
Express News | Apogee Therapeutics Expands Board of Directors With the Appointment of Lisa Bollinger, Md
Here's Why We're Not Too Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Situation
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic